Investment target beaten by almost 150%

Capital will finance CGS’s growth in the dynamic stem cell research sector

Cambridge-based Cell Guidance Systems, which provides products and services for stem cell scientists, has successfully raised £242,800 on the equity crowdfunding platform Crowdcube – exceeding its investment target by a massive 142 per cent. Crowdcube has now helped over 70 British businesses to raise a more than £14.5 million.

A total of 139 people are new shareholders in Cell Guidance Systems, owning a share of 12.14 per cent of the equity in the business. Founded in 2010, the company makes cutting-edge research tools that simplify and accelerate the activities of scientists developing stem cell treatments and undertaking medical research. Its products and services improve methods for tasks such as exosome purification, which are traditionally very time consuming, inefficient and expensive. The company has 200 customers in more than 20 countries.

Cell Guidance Systems will use the investment to support its next stages of growth through increasing marketing, product development and product licensing activities and recruiting additional R&D staff.

Dr Michael Jones of Cell Guidance Systems

Dr Michael Jones of Cell Guidance Systems

Cell Guidance System’s founder, Dr Michael Jones, says: “Reaching our fundraising target will allow us to focus on our long term goals of building our R&D capabilities, IP and product portfolio as well as our reach to the market. Setting up the pitch took quite a lot of effort, but we received full support from Crowdcube and the response from Crowdcube investors was amazing. I'm happy that we chose this funding route.”

Luke Lang, co-founder of Crowdcube, comments: “Cell Guidance System is targeting a fast-growing sector, and we’re excited by the success of its pitch on Crowdcube, which will allow it to take full advantage of the opportunity. Biosciences and stem cell research are a very complex industry and the successful funding clearly demonstrates Crowdcube investors’ growing sophistication and a real appetite for investing in innovative home-grown companies.

Those investing in Cell Guidance Systems are eligible for the Enterprise Investment Scheme (EIS), which offers income tax relief of up to 30 per cent on the amount invested and no capital gains tax on disposal.

Comment Here!